Compare AstraZeneca plc (AZN) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Invesco DB Oil Fund — how do they compare? AstraZeneca plc trades at $158.75 (market cap $248.14B), while Invesco DB Oil Fund trades at $21.05. The key difference: AstraZeneca plc pays a 2.01% dividend while Invesco DB Oil Fund pays none, and Invesco DB Oil Fund is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | DBO | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Commodities - Energy |
52-Week High | $209.48 | $23.80 |
52-Week Low | $147.06 | $11.98 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
DBO trades at $21.03, up 0.86% with a bullish technical signal from moving averages. Recent news highlights oil market volatility due to Middle East tensions and OPEC demand forecast cuts. The stock shows neutral oscillator readings but strong moving average support, indicating underlying strength despite sector headwinds.
The outlook remains cautious due to oil market uncertainties, though technical momentum suggests near-term upside potential. Key risks include geopolitical supply disruptions and demand volatility, while institutional sentiment appears mixed with limited fundamental data available for analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
